The mRNA-1010-P101 clinical trial is evaluating if an investigational mRNA vaccine is safe and effective in preventing the flu in 880 adult participants.

Current seasonal flu vaccines are usually only 60% effective at best, and they often perform poorly during years when the circulating flu strains don’t match the strains selected for that year’s vaccine.

Flu vaccines based on mRNA technology could potentially provide several benefits compared to current vaccines, including the ability to respond to changes in influenza strains more quickly, stronger immune responses, and improved protection in older adults.

On June 7, 2022, Modena announced that the first participants were dosed in the Phase 3 portion of this study.